This index provides a comprehensive guide to clinical trials in neurodegenerative disease research, covering Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, frontotemporal dementia, and other related conditions. It serves as a central hub for understanding the drug development pipeline, trial methodologies, and outcomes across all phases of clinical research.
Clinical trials are essential for developing new treatments and understanding disease progression. Neurodegenerative diseases represent a significant global health burden, with over 50 million people affected by dementia worldwide and approximately 10 million living with Parkinson's disease. The translation of basic science discoveries into clinical applications depends critically on well-designed and executed clinical trials.
| Disease | Trials |
|---|---|
| ALZHEIMER | 4910 |
| PARKINSON | 4613 |
| ALS | 1569 |
| FTD | 380 |
| HUNTINGTON | 285 |
| MSA | 194 |
| DLB | 166 |
| VD | 154 |
| PSP | 154 |
| CBD | 60 |
| Status | Trials |
|---|---|
| Recruiting | 1787 |
| Active Not Recruiting | 506 |
| Not Yet Recruiting | 594 |
| Completed | 6048 |
| Terminated | 737 |
| Withdrawn | 271 |
| Phase | Trials |
|---|---|
| PHASE1 | 1056 |
| PHASE1/PHASE2 | 381 |
| PHASE2 | 1544 |
| PHASE2/PHASE3 | 189 |
| PHASE3 | 816 |
| PHASE4 | 395 |
| EARLY_PHASE1 | 163 |
| NA | 4665 |
| Not Applicable | 2607 |
Total: 11816 trials | Active: 2887 trials
Last updated: 2026-03-18T05:22:53.984245+00:00
Clinical trials proceed through distinct phases. Phase 1 trials focus on safety and dosage in a small group of 20-100 healthy volunteers or patients. Phase 2 trials evaluate efficacy and further assess safety in 100-300 patients. Phase 3 trials confirm efficacy and monitor adverse reactions in larger populations of 300-3,000 patients. Phase 4 trials occur after regulatory approval to monitor long-term effects.
Alzheimer's disease is the most common cause of dementia, affecting an estimated 6.5 million Americans. The AD drug development pipeline includes over 140 agents in various stages of clinical testing. Key trial endpoints include cognitive measures (ADAS-Cog, MoCA, CDR, MMSE), functional measures (ADCS-ADL, BADLS), and biomarkers (Amyloid PET, tau PET, CSF Aβ40/42, p-tau, neurofilament light).
Parkinson's disease affects approximately 1 million Americans, with 60,000 new diagnoses annually. Trials focus on dopaminergic therapies, disease modification, and motor complication management. Key trial endpoints include motor assessments (MDS-UPDRS, Hoehn and Yahr scale), non-motor assessments (NMSS, PDQ-39), and motor complications scales.
Amyotrophic lateral sclerosis affects approximately 30,000 Americans, with a median survival of 2-5 years. The FDA has approved only four treatments: riluzole, edaravone, sodium phenylbutyrate/taurursodiol, and tofersen. Key trial endpoints include functional measures (ALSFRS-R, ALS FVC), survival, and biomarkers (Neurofilament light chain).
Start with the alphabetical listing below to identify the page you need. Then use each page's See Also links to branch into related entities, mechanisms, or disease areas. Key resources for finding active trials include ClinicalTrials.gov, WHO ICTRP, and EU Clinical Trials Register.